-
Fractyl Goes All In on GLP-1 Off-Ramp Drug, Lays of 17% of Workforce
31 Jan 2025 16:57 GMT
… at weight maintenance post-GLP-1 withdrawal while shuttering … trial in weight maintenance post-GLP-1 withdrawal, along with … about $110 million in an initial public offering. The past year has … the company. After the IPO, the company secured Investigational …
-
Pakistan’s Citi Pharma to venture into real estate sector
07 Feb 2025 09:21 GMT
… , Glargine, Lispro, Aspart, Detemir, Degludec), GLP-1 (Semaglutide and Bio-similar … the hospital proceeds from an Initial Public Offering (IPO) in the establishment of its …
-
GLP-1RA developer Metsera targets $289m IPO
28 Jan 2025 18:51 GMT
… like peptide-1 receptor agonist (GLP-1RA) asset MET-097i … an increasingly crowded field of GLP-1RAs where makers are trying … plans for a $131m Nasdaq IPO, while Ascentage Pharma – already … targeting a lucrative market, with GLP-1RA therapies forecast to bring …
-
Metsera Seeks $289M Raise, $1.78B Valuation in IPO
27 Jan 2025 21:39 GMT
… an injectable, long-acting GLP-1 receptor agonist. In early … The substantial financing and large IPO targets set by Metsera are … frequent injections.
The IPO market for GLP-1 agonists has gained … . Carmot Therapeutics, yet another GLP-1 developer, had plans to …
-
Obesity-Focused Aardvark Therapeutics Files IPO to Advance Lead Candidate
24 Jan 2025 15:59 GMT
… Aardvark Therapeutics filed for an IPO Thursday, following competitor Metsera, … and Eli Lilly in the GLP-1 space, Aardvark is … eventual release of GLP-1, the related molecule GLP-2 and the … fellow obesity player Metsera into IPO waters. The fast-moving …
-
Diabetes startup Virta Health is now prescribing Ozempic for weight loss in a push toward profitability and IPO
23 Jan 2025 10:04 GMT
… of a potential IPO.
Virta Health has prescribed GLP-1 medications … obesity in 2020.
While GLP-1 medications were originally developed … platform Sequence to offer GLP-1 medications to its … increasingly honed their strategies for GLP-1 coverage. Previously, he …
-
BIOA DEADLINE APPROACHING: BFA Law Notifies BioAge Investors to Contact the Firm before the Upcoming March 10 Class Action Deadline (NASDAQ:BIOA)
06 Feb 2025 12:18 GMT
… ’s registration statement for its initial public offering held on or about September … loss. As alleged, BioAge’s IPO documents discussed its ongoing STRIDES … of azelaprag in combination with GLP-1R agonists for enhanced weight …
-
Nine-month-old obesity player Metsera files an IPO
13 Jan 2025 14:41 GMT
… , BioAge, completed an upsized IPO that raised $198 million, … week.
According to its IPO prospectus, Metsera has already … monotherapy and in combination with GLP-1-acting drugs, including … reports have estimated that GLP-1 receptor agonists represented …
-
In brief: Medline’s IPO, GLP-1's expansion, DME’s ‘hidden cost,’ Nymbl’s investment
03 Jan 2025 16:28 GMT
… Exchange Commission for a proposed initial public offering of its common stock.
The … succession planning process.
FDA approves GLP-1 for OSA
WASHINGTON – The … intestine (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic …
-
BIOA CLASS ACTION DEADLINE: The BioAge Court Deadline is Approaching – Contact BFA Law by March 10 (NASDAQ:BIOA)
04 Feb 2025 13:18 GMT
… ’s registration statement for its initial public offering held on or about September … loss. As alleged, BioAge’s IPO documents discussed its ongoing STRIDES … of azelaprag in combination with GLP-1R agonists for enhanced weight …
About
© 1995-2025